Biorestorative Therapies (NASDAQ:BRTX – Get Free Report) is expected to be releasing its Q2 2026 resultson Wednesday, November 11th. Analysts expect the company to announce earnings of ($1.40) per share and revenue of $0.65 million for the quarter. Investors can check the company’s upcoming Q2 2026 earnings report page for the latest details on the call scheduled for Tuesday, November 17, 2026 at 3:30 PM ET.
Biorestorative Therapies Trading Up 5.3%
Shares of NASDAQ:BRTX opened at $1.60 on Tuesday. Biorestorative Therapies has a 12 month low of $1.28 and a 12 month high of $29.00. The company’s fifty day moving average price is $2.18 and its 200 day moving average price is $5.83.
Wall Street Analyst Weigh In
BRTX has been the topic of a number of recent research reports. Weiss Ratings restated a “sell (e+)” rating on shares of Biorestorative Therapies in a report on Monday, August 24th. Maxim Group cut shares of Biorestorative Therapies from a “buy” rating to a “hold” rating in a report on Tuesday, October 6th. One equities research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Biorestorative Therapies presently has an average rating of “Reduce”.
Biorestorative Therapies Company Profile
BioRestorative Therapies, Inc is a biotechnology company focused on developing regenerative medicine products using cell and tissue-based technologies. The company’s programs are intended to address conditions for which existing treatment options may be limited, including musculoskeletal and metabolic disorders.
Its lead product candidate, BRTX-100, is an autologous cell therapy developed from a patient’s own bone marrow and designed to treat painful lumbar disc disease, including chronic lower-back pain associated with degenerated discs.
Featured Stories
- Five stocks we like better than Biorestorative Therapies
- Wall Street May Be Making a Big Mistake With monday.com Stock
- Are These 2 Mid-Cap Growth Stocks Worth the Risk?
- Oklo Changes the Narrative: Does a Nuclear Stock Price Explosion Come Next?
- Cloudflare’s 20% Sell-Off May Have Created an Opening for Investors
Receive News & Ratings for Biorestorative Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biorestorative Therapies and related companies with MarketBeat.com's FREE daily email newsletter.
